Oncolytics Biotech Inc. (ONCY)

[Noodle2]

Did March 16 news get the attention of anyone? Since March 2, there was a gradual uptick in stock price because of the announcement of upcoming results in Canada? Mid-way, on March 16, the news of the collaboration trial with Celgene and Oncolytics was made public. The PR seemed to go unnoticed:

"Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma"

"This trial, the first of its kind, is a novel way of activating a patient's own immune system to target their myeloma (immunotherapy) using a natural virus and lenalidomide or pomalidomide, which could offer a new treatment strategy in myeloma," said MUK eleven Chief Investigator Gordon Cook, Consultant Haematologist at Leeds Teaching Hospitals Trust....This clinical study expands on earlier pre-clinical work by Professor Cook that demonstrates that REOLYSIN has dual modes of action against multiple myeloma; being both directly cytotoxic and also activating immune effector cells to target and destroy cancer cells. Further, this immune-mediated activity can be enhanced by immunomodulatory agents to eliminate disease."

http://web.tmxmoney.com/article.php?newsid=5034329226102112&qm_symbol=ONC

From PharmaTimes online (March 17)- "Myeloma UK launches ‘world first’ immunotherapy trial"

"Explaining the premise for the trial, Myeloma UK noted that Reolysin has been shown to be effective in killing a range of cancer cells including myeloma cells, and that research from the University of Leeds has suggested an increase in immune activation when the drug is combined with immmunotherapies."

http://www.pharmatimes.com/news/myeloma_uk_launches_world_first_immunotherapy_trial_1189127